NGL Fine Chem Ltd
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]
- Market Cap ₹ 930 Cr.
- Current Price ₹ 1,504
- High / Low ₹ 2,161 / 957
- Stock P/E 44.6
- Book Value ₹ 457
- Dividend Yield 0.12 %
- ROCE 9.44 %
- ROE 7.75 %
- Face Value ₹ 5.00
Pros
- Company's working capital requirements have reduced from 64.9 days to 50.4 days
Cons
- Stock is trading at 3.29 times its book value
- Company has a low return on equity of 11.4% over last 3 years.
- Dividend payout has been low at 4.34% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 153 | 152 | 258 | 318 | 278 | 339 | 368 | 382 | |
| 121 | 130 | 178 | 249 | 243 | 285 | 333 | 348 | |
| Operating Profit | 32 | 22 | 80 | 68 | 35 | 54 | 35 | 34 | 
| OPM % | 21% | 14% | 31% | 21% | 13% | 16% | 9% | 9% | 
| 4 | 1 | 8 | 11 | 6 | 14 | 9 | 10 | |
| Interest | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 
| Depreciation | 6 | 8 | 8 | 10 | 11 | 12 | 12 | 14 | 
| Profit before tax | 28 | 12 | 78 | 67 | 27 | 54 | 28 | 27 | 
| Tax % | 27% | 31% | 27% | 25% | 25% | 24% | 24% | |
| 20 | 8 | 57 | 50 | 20 | 41 | 21 | 21 | |
| EPS in Rs | 32.58 | 13.50 | 91.81 | 80.77 | 33.18 | 66.88 | 34.19 | 33.78 | 
| Dividend Payout % | 5% | 13% | 2% | 2% | 5% | 3% | 5% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 19% | 
| 3 Years: | 5% | 
| TTM: | 6% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 17% | 
| 3 Years: | -25% | 
| TTM: | -50% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% | 
| 5 Years: | 11% | 
| 3 Years: | -2% | 
| 1 Year: | -24% | 
| Return on Equity | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 18% | 
| 3 Years: | 11% | 
| Last Year: | 8% | 
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 
| Reserves | 89 | 96 | 151 | 200 | 219 | 260 | 279 | 
| 27 | 28 | 16 | 30 | 32 | 34 | 77 | |
| 23 | 26 | 36 | 44 | 32 | 59 | 74 | |
| Total Liabilities | 142 | 154 | 207 | 277 | 287 | 356 | 433 | 
| 61 | 68 | 64 | 89 | 88 | 86 | 143 | |
| CWIP | 0 | 0 | 12 | 6 | 26 | 46 | 50 | 
| Investments | 9 | 11 | 29 | 29 | 39 | 54 | 60 | 
| 73 | 75 | 102 | 153 | 133 | 171 | 181 | |
| Total Assets | 142 | 154 | 207 | 277 | 287 | 356 | 433 | 
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 9 | 20 | 27 | 14 | 35 | 20 | 36 | |
| -10 | -20 | -25 | -14 | -27 | -27 | -35 | |
| 0 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Net Cash Flow | -1 | -0 | 2 | -1 | 7 | -7 | 0 | 
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 79 | 63 | 53 | 74 | 86 | 97 | 81 | 
| Inventory Days | 106 | 155 | 132 | 137 | 69 | 98 | 101 | 
| Days Payable | 92 | 116 | 103 | 91 | 63 | 112 | 113 | 
| Cash Conversion Cycle | 93 | 102 | 82 | 120 | 93 | 83 | 68 | 
| Working Capital Days | 70 | 58 | 69 | 90 | 68 | 76 | 50 | 
| ROCE % | 14% | 54% | 34% | 12% | 20% | 9% | 
Documents
Announcements
- 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            3 Oct - Reg.74(5) certificate for dematerialisation during 01-Jul-2025 to 30-Sep-2025, listing confirmed.
- Closure of Trading Window 26 Sep
- 
        
          Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
          
            19 Aug - AGM on 19 Aug 2025: all eight resolutions passed; final dividend Rs1.75/share; MD reappointment; auditor appointments.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 19 Aug
- 
        
          Regulation 30 Updates
          
            7 Aug - Rs.119.83 Cr invested in plant expansion for future growth in Q1 FY 2025-26.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Concalls
- 
      Aug 2025TranscriptNotesPPT
- 
      May 2025Transcript PPT
- 
      Feb 2025TranscriptNotesPPT
- 
      Nov 2024Transcript PPT
- 
      Aug 2024TranscriptNotesPPT
- 
      Jun 2024Transcript PPT REC
- 
      May 2024TranscriptNotesPPT
- 
      Feb 2024TranscriptNotesPPT
- 
      Nov 2023TranscriptPPT
- 
      Nov 2023Transcript PPT REC
- 
      Aug 2023TranscriptNotesPPT
- 
      May 2023Transcript PPT
- 
      Feb 2023TranscriptNotesPPT
- 
      Nov 2022Transcript PPT
- 
      Aug 2022Transcript PPT
- 
      May 2022Transcript PPT
- 
      Feb 2022Transcript PPT
- 
      Nov 2021Transcript PPT
- 
      Aug 2021Transcript PPT
- 
      Jun 2021TranscriptNotesPPT
- 
      Jun 2021Transcript PPT
- 
      Nov 2020TranscriptPPT
- 
      Jul 2020TranscriptPPT
- 
      Dec 2019TranscriptPPT
Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.
Product Profile:[3][4]
It has ~39 APIs (37 Veterinary APIs, 2 Human APIs), ~4 Intermediates, and ~12 finished dosage forms, etc., in the categories of Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements